Micreos

Micreos is a private, pre-clinical stage biotech leveraging a proprietary engineered endolysin platform to develop targeted, resistance-resistant protein therapeutics. The company's lead candidate, MEndoB, is being developed for Atopic Dermatitis (AD), targeting the pathogenic S. aureus that aggravates the condition, with plans to enter clinical trials in late 2026. With a seasoned leadership team and a focused strategy on high-unmet-need dermatology, Micreos aims to establish a foundational therapy for AD and potentially expand into other indications driven by pathogenic triggers.

Proprietary platform for engineering recombinant endolysin proteins. These proteins are optimized to selectively target and kill specific pathogenic bacteria (e.g., S. aureus) by breaking down their cell walls, while sparing the beneficial microbiome. The platform enables engineering for specificity, environmental stability (e.g., acidic skin pH), and a low propensity for bacterial resistance development.

In Atopic Dermatitis, Micreos will compete against a wide range of therapies including topical corticosteroids/calcineurin inhibitors, PDE4 inhibitors (crisaborole), JAK inhibitors (topical and oral), and biologic injectables (dupilumab, tralokinumab, etc.). Its differentiation lies in its specific antibacterial mechanism targeting S. aureus, a pathogenic driver, rather than directly modulating the host immune response. It may face competition from other microbiome-focused approaches and antimicrobial peptides.